Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development.

An unprecedented number of new cancer targets are in development, and most are being developed in combination therapies. Early oncology development is strategically challenged in choosing the best combinations to move forward to late stage development. The most common early endpoints to be assessed in such decision-making include objective response rate, duration of response and tumor size change. In this paper, using independent-drug-action and Bliss-drug-independence concepts as a foundation, we introduce simple models to predict combination therapy efficacy for duration of response and tumor size change. These models complement previous publications using the independent action models (Palmer 2017, Schmidt 2020) to predict progression-free survival and objective response rate and serve as new predictive models to understand drug combinations for early endpoints. The models can be applied to predict the combination treatment effect for early endpoints given monotherapy data, or to estimate the possible effect of one monotherapy in the combination if data are available from the combination therapy and the other monotherapy. Such quantitative work facilitates strategic planning and decision making in early stage oncology drug development.

[1]  Hemant Ishwaran,et al.  Estimating Individual Treatment Effect in Observational Data Using Random Forest Methods , 2017, Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America.

[2]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[3]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[4]  R. Pazdur,et al.  FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma , 2017, The oncologist.

[5]  T. Choueiri,et al.  Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. , 2015, European urology.

[6]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[7]  Fan Li,et al.  Addressing Extreme Propensity Scores via the Overlap Weights , 2018, American journal of epidemiology.

[8]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[9]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[10]  M. Ahn,et al.  4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. , 2018 .

[11]  P. Sorger,et al.  Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors , 2020 .

[12]  M. Boakye,et al.  Propensity scores based methods for estimating average treatment effect and average treatment effect among treated: A comparative study , 2017, Biometrical journal. Biometrische Zeitschrift.

[13]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[14]  J. Wolchok,et al.  Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. , 2014, Cancer treatment reviews.

[15]  F. Liu,et al.  Independent drug action and its statistical implications for development of combination therapies. , 2020, Contemporary clinical trials.

[16]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[17]  Peter K. Sorger,et al.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.

[18]  Y. Bang,et al.  Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. , 2019, Journal of Clinical Oncology.

[19]  M. Ross,et al.  Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials , 2017, Journal of Immunotherapy for Cancer.

[20]  N. Reinmuth,et al.  Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[21]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[22]  Y. Bang,et al.  Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.

[23]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Advani,et al.  Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. , 2020, The Lancet. Haematology.

[25]  E. Elgabry,et al.  Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study , 2019, JAMA oncology.

[26]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[27]  T. Powles,et al.  LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 , 2020 .

[28]  Hongwei Wang,et al.  Proportion of treatment effect (PTE) explained by a surrogate marker , 2003, Statistics in medicine.

[29]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[30]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Keegan,et al.  FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type. , 2019, Journal of Clinical Oncology.

[32]  E. Schmidt,et al.  Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials. , 2020, JAMA network open.